Clinical Trials Logo

Hyperphosphatemia clinical trials

View clinical trials related to Hyperphosphatemia.

Filter by:

NCT ID: NCT06406140 Enrolling by invitation - Clinical trials for End-stage Renal Disease

Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients

Start date: March 15, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to learn if Niacin has an effect on lipoprotein (a) concentration and hyperphosphatemia, which represent strong risk factors for cardiovascular diseases, in End-stage renal disease (ESRD) patients undergoing hemodialysis. It will also learn about the safety of Niacin. The main questions it aims to answer are: - Does Niacin lower lipoprotein (a) concentration? - Does Niacin treat hyperphosphatemia in End-stage renal disease (ESRD) patients undergoing hemodialysis? Researchers will compare Niacin to a control group (taking no drug) to see if drug Niacin works to treat hyperphosphatemia and lower lipoprotein (a) concentration. Participants will: - Take drug Niacin or no drug every day for 3 months - Visit the clinic once every 2 weeks for checkups and tests All Patients will be subjected to the following: 1. Informed consent. 2. Demographics and history taking: Using Patient Data sheet. 3. Laboratory evaluation including: Kidney function tests: blood urea,serum creatinine, albumin ,uric acid. Complete blood count (CBC). Lipid profile:Lipoprotein (a),total cholesterol,triglyceride,high density lipoprotein (HDL), low density lipoprotein (LDL). Phosphorous, calcium, sodium, parathyroid hormone (PTH), alkaline phosphatase (ALP). C-reactive protein (CRP).

NCT ID: NCT06206135 Recruiting - Hyperphosphatemia Clinical Trials

Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

Start date: December 21, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.

NCT ID: NCT06186934 Recruiting - Hyperphosphatemia Clinical Trials

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Start date: December 21, 2023
Phase:
Study type: Observational [Patient Registry]

The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of Nephoxil capsule 500 mg (Ferric Citrate 500 mg, equivalent to 105 mg Ferric Iron) in routine clinical settings

NCT ID: NCT05897502 Completed - Hyperphosphatemia Clinical Trials

Explore the Effectors of The Transtheoretical Model on Nutritional Education in Patients on Hemodialysis

Start date: July 4, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the improvement degree of nutritional care program on the nutritional status and eating habits of hemodialysis patients

NCT ID: NCT05764590 Completed - Clinical trials for Chronic Kidney Diseases

A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: - How much effect AP-306 has assessed by blood phosphorus lowering; - How safe and tolerable AP-306 is. Participants will receive either following treatments: - AP-306, and - Sevelamer carbonate.

NCT ID: NCT05699239 Completed - Clinical trials for Hyperphosphatemia Patients on Hemodialysis

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Start date: February 8, 2023
Phase: Phase 2
Study type: Interventional

A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis

NCT ID: NCT05577507 Completed - Clinical trials for Chronic Kidney Diseases

Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients

Start date: March 30, 2023
Phase: Phase 4
Study type: Interventional

The aim of the study is to evaluate the efficacy and safety of cholestyramine in the management of hyperphosphatemia in hemodialysis patients. Colestilan is a non-metallic phosphate binder that acts as an anion-exchange resin. Colestilan itself is not absorbed after oral administration, and it is able to bind dietary phosphate within the gastrointestinal tract and thus prevent absorption of the mineral. Initial, Phase II, studies showed that it reduces serum phosphorus levels in dialysis patients with hyperphosphatemia without affecting serum calcium levels. There are no studies conducted about the feasibility and efficacy of cholestyramine as an oral phosphate binder in hemodialysis patients. Relying on the efficacy and safety of bile acid sequestrants such as colestilan and colestipol in the management of hyperphosphatemia and hypercholesterolemia in hemodialysis patients, cholestyramine is selected to be studied in hemodialysis patients. A total of 80 patients will be recruited and divided into 2 groups: - Group 1: (cholestyramine 12 gram), 40 patients will take a dose of cholestyramine 4-gram sachet in 150-200 ml water or juice three times daily within meals as an add on therapy with standard therapy calcium-based phosphate binder (Calcimate). Group 2: Control group, 40 patients will take only the standard therapy calcium-based phosphate binder (Calcimate). Time of the trial will be two months (8 weeks trial period) Baseline characteristics: The following data will be collected from all patients at baseline 1. Age, sex, weight, duration of ESRD and hemodialysis comorbidities. 2. Dialysis duration, serum phosphate level, serum calcium level, iPTH, BUN, Cr (mg/d L), Albumin (mg/d L), Hb (g m%), renal function test, liver function test, blood glucose level, TG, total cholesterol level, LDL-C, HDL.C. After the end of trial, we will examine if cholestyramine has a significant efficacy on reducing serum phosphate level in adult hemodialysis patients.

NCT ID: NCT05569109 Not yet recruiting - AV Fistula Clinical Trials

av Fistula Patency Loss as a Cause of Fistula Failure and Hyperphosphatemia

Start date: December 1, 2022
Phase:
Study type: Observational

Assessment of arteriovenous fistula patency loss which leads to av fistula failure and its relation to high serum phosphate level in chronic hemodialysis patients.

NCT ID: NCT05439980 Recruiting - Clinical trials for Chronic Kidney Diseases

Improving Phosphate Control in Children With CKD

IMPACT
Start date: June 20, 2023
Phase:
Study type: Observational

Research goals: To explore the views and baseline knowledge of children and young people (CYP) with CKD and their caregivers to develop effective phosphate educational materials (PEM), adapted for age, and acknowledging different learning styles

NCT ID: NCT05389826 Active, not recruiting - Clinical trials for Dialysis Related Complication

mHealth for Phosphorus Management in CKD.

PHOSFO_OK
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The project aims to generate an mHealth environment in which CKD patients are empowered in terms of the self-management of their hyperphosphatemia pathology, while under medical supervision. Such environment will allow nephrologists to inform patients beyond their traditional point-of-care and will allow patients to provide feedback on their condition in a timely manner that benefits the CKD collective. In this way we delve in a technological area that has been argued that remains underutilized within nephrology (1) and that should be perceived as an opportunity for CKD (2). In our work, we will build from recent related efforts in the control of hyperphosphatemia (3).